Premium
COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)
Author(s) -
Jurczak W.,
Zinzani P. L.,
Cunningham D.,
Yavrom S.,
Huang W.,
Gorbatchevsky I.,
Ribrag V.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.174_2880
Subject(s) - medicine , rituximab , oncology , adverse effect , regimen , lymphoma , refractory (planetary science) , gastroenterology , physics , astrobiology